Department of Bioinformatics and Computational Biology, MD Anderson Cancer Center, Houston, TX, USA.
Cancer J. 2012 Jan-Feb;18(1):107-14. doi: 10.1097/PPO.0b013e3182431c57.
Glioblastoma multiforme is a histopathologically heterogeneous disease with few treatment options. Therapy based on genomic alterations is rapidly gaining popularity because of the high response rate and high specificity. DNA copy number and exon-sequencing studies of glioblastoma multiforme samples have revealed recurrent genomic alterations in genes such as TP53, EGFR, and IDH1, but to date, this has not resulted in novel glioblastoma multiforme therapies. Identification of expression subtypes has resulted in new insights such as the association between genomic abnormalities and expression signatures. This review describes the types of genomic studies that have been performed and that are underway, the most prominent results, and the implications of genomic research for the development of clinical treatment modalities.
胶质母细胞瘤是一种组织病理学上具有异质性的疾病，治疗选择有限。基于基因组改变的治疗方法由于高反应率和高特异性而迅速流行。对胶质母细胞瘤样本的 DNA 拷贝数和外显子测序研究揭示了 TP53、EGFR 和 IDH1 等基因中反复出现的基因组改变，但迄今为止，这并未导致新的胶质母细胞瘤治疗方法。表达亚型的鉴定导致了新的见解，例如基因组异常与表达特征之间的关联。本文综述了已进行和正在进行的基因组研究类型、最显著的结果以及基因组研究对临床治疗模式发展的意义。
